Prot# SILCAAT: A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts Under Active Antiretroviral Therapy (the "SILCAAT Trial")

Project: Research project

Project Details

StatusFinished
Effective start/end date2/18/03 → 12/31/08

Funding

  • University of Minnesota (SILCAAT)
  • Chiron Corporation (SILCAAT)